Protagonist Therapeutics, Inc. (PTGX) Technical Analysis & Indicators

Protagonist Therapeutics, Inc. (PTGX) — Price $144.85 (closing price, October 30, 2026) — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Technical analysis of Protagonist Therapeutics, Inc. (PTGX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.

Price Performance

1 month+3.42%
3 months+6.66%
Year-to-date+65.85%
1 year+84.24%
3 years+769.97%
5 years+339.87%
10 years+692.83%

52-Week Range

52-week High$160.81
52-week Low$75.44
Avg Volume (90d)682K

Technical Indicators

SMA 50$142.93
SMA 200$116.62
Beta2.11
30-day Volatility (annualised)34.2%
Price vs SMA 50+1.3%
Price vs SMA 200+24.2%

Monthly Close (12 months)

MonthCloseChange
2025-12$87.34
2026-01$81.80-6.3%
2026-02$92.08+12.6%
2026-03$105.40+14.5%
2026-04$98.97-6.1%
2026-05$99.56+0.6%
2026-06$122.58+23.1%
2026-07$136.64+11.5%
2026-08$147.75+8.1%
2026-09$140.89-4.6%
2026-10$144.85+2.8%

Upcoming Earnings

DateEPS Est.Revenue Est.
2026-11-05$2.50$238M
2026-08-05$2.23$199M
2026-05-05$-0.65$12M
2026-02-25$-0.53$9M
2025-11-06$-0.59$15M
2025-08-06$-0.53$8M
2025-05-06$-0.50$7M

Price

Price$144.85 (closing price, October 30, 2026)
Market Cap$9.4B
ExchangeNASDAQ
CountryUS

Valuation Ratios

P/E Ratio140.13
Price / Book11.35
Dividend Yield0.00%

Financial Health

Debt / Equity0.01
Current Ratio21.71
Piotroski F-Score3
Altman Z-Score59.63

Related companies: IMVT · SYRE · IRON · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L

Explore sector: Healthcare · Biotechnology

More sections of PTGX: Overview · Financials · Valuation · Statistics · Estimates · Ownership · News · Events

Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks